title: Protein chaperones: a composition of matter review (2008 - 2013).
abstract: BACKGROUND
  Heat shock proteins (Hsps) are proteins with important functions in regulating disease phenotypes. Historically, Hsp90 has first received recognition as a target in cancer, with consequent efforts extending its potential role to other diseases. Hsp70 has also attracted interest as a therapeutic target for its role as a co-chaperone to Hsp90 as well as its own anti-apoptotic roles.
  
  
  METHODS
  Herein, patents from 2008 to 2013 are reviewed to identify those that disclose composition of matter claimed to inhibit Hsp90 or Hsp70.
  
  
  CONCLUSIONS
  For Hsp90, there has been considerable creativity in the discovery of novel pharmacophores that fall outside the three initially discovered scaffolds (i.e., ansamycins, resorcinols and purines). Nonetheless, much of the patent literature appears to build on previously reported structure activity relationship through slight modifications of Hsp90 inhibitor space by finding weaknesses in existing patents. The major goal of future development of Hsp90 inhibitors is not necessarily identifying better molecules but rather understanding how to rationally use these agents in the clinic. The development of Hsp70 inhibitors has lagged behind. It will require a more concerted effort from the drug discovery community in order to begin to realize the potential of this target.
authors.affiliation: Memorial Sloan-Kettering Cancer Center, Program in Molecular Pharmacology and Chemistry and Department of Medicine , NY , USA.
authors.forename: Tony
authors.initials: T
authors.lastname: Taldone
authors.forename: Hardik J
authors.initials: HJ
authors.lastname: Patel
authors.forename: Alexander
authors.initials: A
authors.lastname: Bolaender
authors.forename: Maulik R
authors.initials: MR
authors.lastname: Patel
authors.forename: Gabriela
authors.initials: G
authors.lastname: Chiosis
mesh_terms: D000818:Animals; D055808:Drug Discovery; D006360:Heat-Shock Proteins / Q000037:antagonists & inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D018832:Molecular Chaperones / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D009369:Neoplasms / Q000188:drug therapy; D010330:Patents as Topic
chemical_list: D006360:Heat-Shock Proteins; D018832:Molecular Chaperones
references.citation: J Med Chem. 2005 Apr 21;48(8):2892-905
references.pmid: 15828828
references.citation: Cell Stress Chaperones. 1998 Jun;3(2):100-8
references.pmid: 9672245
references.citation: Nat Chem Biol. 2013 Nov;9(11):677-84
references.pmid: 23995768
references.citation: J Clin Invest. 2010 Oct;120(10):3578-93
references.pmid: 20852385
references.citation: Curr Top Med Chem. 2006;6(11):1215-25
references.pmid: 16842158
references.citation: Angew Chem Int Ed Engl. 2008;47(39):7466-9
references.pmid: 18729127
references.citation: Chem Biol. 2013 Dec 19;20(12):1469-80
references.pmid: 24239008
references.citation: Pharmacol Ther. 1998 Aug;79(2):129-68
references.pmid: 9749880
references.citation: Cancer Detect Prev. 1998;22(6):549-55
references.pmid: 9824379
references.citation: J Med Chem. 2005 Dec 1;48(24):7503-12
references.pmid: 16302791
references.citation: Chem Biol. 2011 Feb 25;18(2):210-21
references.pmid: 21338918
references.citation: Cell Mol Immunol. 2004 Aug;1(4):274-9
references.pmid: 16225770
references.citation: Biochim Biophys Acta. 2012 Mar;1823(3):742-55
references.pmid: 22062686
references.citation: Nat Med. 2009 Dec;15(12):1369-76
references.pmid: 19966776
references.citation: Mol Neurodegener. 2010 Jun 03;5:24
references.pmid: 20525284
references.citation: Cell Cycle. 2009 Feb 15;8(4):518-26
references.pmid: 19197160
references.citation: Curr Top Med Chem. 2008;8(10):859-68
references.pmid: 18673171
references.citation: Int J Cancer. 2010 Mar 1;126(5):1226-34
references.pmid: 19676042
references.citation: Bioorg Med Chem. 2013 Nov 15;21(22):7047-63
references.pmid: 24100158
references.citation: Cancer Cell. 2008 Sep 9;14(3):250-62
references.pmid: 18772114
references.citation: J Med Chem. 2010 Jan 14;53(1):3-17
references.pmid: 20055425
references.citation: J Med Chem. 1997 Sep 26;40(20):3151-60
references.pmid: 9379434
references.citation: Bioorg Med Chem. 2009 Mar 15;17(6):2225-35
references.pmid: 19017562
references.citation: Cancer Res. 2011 Jan 15;71(2):484-95
references.pmid: 21224349
references.citation: Mol Cancer Ther. 2009 Apr;8(4):921-9
references.pmid: 19372565
references.citation: J Med Chem. 2013 Sep 12;56(17):6803-18
references.pmid: 23965125
references.citation: Curr Top Med Chem. 2009;9(15):1337-51
references.pmid: 19860737
references.citation: Biochem Pharmacol. 1999 Apr 15;57(8):877-80
references.pmid: 10086320
references.citation: Expert Opin Drug Discov. 2011 May;6(5):559-587
references.pmid: 22400044
references.citation: Curr Top Med Chem. 2009;9(15):1447-61
references.pmid: 19860731
references.citation: J Neurosci. 2009 Sep 30;29(39):12079-88
references.pmid: 19793966
references.citation: Ther Drug Monit. 1995 Dec;17(6):700-3
references.pmid: 8588244
references.citation: J Med Chem. 2007 Jun 14;50(12):2767-78
references.pmid: 17488003
references.citation: Mol Cell. 2010 Aug 13;39(3):321-31
references.pmid: 20705236
references.citation: Drug Metab Dispos. 2008 Oct;36(10):2050-7
references.pmid: 18635747
references.citation: Mol Cell. 2009 Oct 9;36(1):15-27
references.pmid: 19818706
references.citation: Annu Rev Biochem. 2013;82:323-55
references.pmid: 23746257
references.citation: Cancer Res. 1992 Dec 15;52(24):6926-30
references.pmid: 1458481
references.citation: Mol Cancer Res. 2013 Mar;11(3):219-29
references.pmid: 23303345
references.citation: Mol Cancer Ther. 2010 Apr;9(4):906-19
references.pmid: 20371713
references.citation: J Med Chem. 2006 Aug 10;49(16):4953-60
references.pmid: 16884307
references.citation: Nature. 2003 Sep 25;425(6956):407-10
references.pmid: 14508491
references.citation: J Med Chem. 2006 Jan 12;49(1):381-90
references.pmid: 16392823
references.citation: Curr Pharm Des. 2013;19(3):377-86
references.pmid: 22920905
references.citation: J Immunol. 2011 Jan 1;186(1):563-75
references.pmid: 21131419
references.citation: J Biol Chem. 2004 Dec 3;279(49):51131-40
references.pmid: 15448148
references.citation: Biochem J. 1994 Jun 1;300 ( Pt 2):567-75
references.pmid: 8002963
references.citation: Drug Discov Today. 2010 May;15(9-10):342-53
references.pmid: 20230904
references.citation: Nat Chem Biol. 2011 Sep 25;7(11):818-26
references.pmid: 21946277
references.citation: Chem Biol. 2001 Mar;8(3):289-99
references.pmid: 11306353
references.citation: J Mol Biol. 2011 Aug 19;411(3):614-32
references.pmid: 21708173
references.citation: J Biol Chem. 2001 Jan 12;276(2):910-4
references.pmid: 11036084
references.citation: Proc Natl Acad Sci U S A. 2009 May 19;106(20):8368-73
references.pmid: 19416831
references.citation: J Med Chem. 2009 Aug 13;52(15):4794-809
references.pmid: 19610616
references.citation: J Med Chem. 2009 Mar 26;52(6):1510-3
references.pmid: 19256508
references.citation: J Med Chem. 2010 Oct 28;53(20):7280-6
references.pmid: 20608738
references.citation: Nat Rev Drug Discov. 2002 Sep;1(9):665-73
references.pmid: 12209147
references.citation: Clin Cancer Res. 2009 Jun 15;15(12):4046-57
references.pmid: 19509149
references.citation: Pathol Res Pract. 2000;196(10):665-73
references.pmid: 11087053
references.citation: Nat Rev Mol Cell Biol. 2013 Oct;14(10):630-42
references.pmid: 24026055
references.citation: Proc Natl Acad Sci U S A. 2007 May 29;104(22):9511-6
references.pmid: 17517623
references.citation: J Med Chem. 2010 Jun 24;53(12):4585-602
references.pmid: 20334364
references.citation: Nat Rev Cancer. 2010 Aug;10(8):537-49
references.pmid: 20651736
references.citation: Expert Opin Ther Pat. 2011 Oct;21(10):1501-42
references.pmid: 21689065
references.citation: J Antibiot (Tokyo). 1982 Aug;35(8):939-47
references.pmid: 7142012
references.citation: Mol Cancer Res. 2011 Jul;9(7):936-47
references.pmid: 21636681
references.citation: Nat Rev Mol Cell Biol. 2010 Jul;11(7):515-28
references.pmid: 20531426
references.citation: Lancet Oncol. 2013 Aug;14(9):e358-69
references.pmid: 23896275
references.citation: J Med Chem. 1998 Jan 1;41(1):130-42
references.pmid: 9438030
references.citation: Cancer Res. 2000 Dec 15;60(24):6818-21
references.pmid: 11156371
references.citation: Nat Chem Biol. 2007 Aug;3(8):498-507
references.pmid: 17603540
references.citation: J Med Chem. 2012 Sep 13;55(17):7480-501
references.pmid: 22913511
references.citation: Int J Cancer. 2010 Mar 1;126(5):1216-25
references.pmid: 19662650
references.citation: Eur J Cancer. 1997 May;33(6):873-7
references.pmid: 9291808
references.citation: J Am Chem Soc. 2011 Dec 21;133(50):20267-76
references.pmid: 22074182
references.citation: Nat Chem Biol. 2006 Sep;2(9):474-9
references.pmid: 16862141
references.citation: J Med Chem. 2012 Sep 13;55(17):7786-95
references.pmid: 22938030
references.citation: Clin Cancer Res. 2012 Jan 1;18(1):64-76
references.pmid: 22215907
references.citation: Hum Pathol. 1998 Oct;29(10):1050-5
references.pmid: 9781640